Function of mitochondrial pyruvate carriers in hepatocellular carcinoma patients

Ma,Xiangming; Cui,Yunlong; Zhou,Hongyuan; Li,Qiang

doi:10.3892/ol.2018.8466

Function of mitochondrial pyruvate carriers in hepatocellular carcinoma patients

Authors:
- Xiangming Ma
- Yunlong Cui
- Hongyuan Zhou
- Qiang Li
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin 300060, P.R. China
Published online on: April 11, 2018 https://doi.org/10.3892/ol.2018.8466
Pages: 9110-9116
Copyright: © Ma et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mitochondrial pyruvate carriers (MPC) have been identified as a critical component of energy metabolism in the cancer cells of multiple malignant tumor types. The aim of the present study was to investigate the association between the expression of MPC1 and MPC2 and the prognosis of patients with hepatocellular carcinoma (HCC). A total of 85 formalin‑fixed paraffin‑embedded HCC tissues were assessed using immunohistochemistry. A further 20 fresh pathological specimens, including cancer and adjacent normal liver tissues from patients who had undergone a hepatectomy, were analyzed using western blotting and reverse transcription‑quantitative polymerase chain reaction. The relative expression of MPC1 and MPC2 was quantified using Image‑Pro Plus software, and the association between MPC expression and clinical outcomes was analyzed by Student's t‑test. MPC1 and MPC2 protein expression was significantly downregulated in HCC, but no association was identified between the expression of MPC1 or MPC2 and the clinicopathological characteristics of the patients. MPC1 mRNA levels were decreased in each cancer sample, while a mixture of increased and decreased MPC2 mRNA levels observed in the HCC samples. Multivariate regression analysis indicated that the protein level and the microvascular invasion of MPC1 were positively associated with the recurrence of HCC (P=0.000 and P=0.017, respectively). MPC1 may therefore serve as an attractive biomarker for the identification of patients with HCC at a high risk of recurrence following curative resection.

View Figures

View References

1	Fitzmorris P, Shoreibah M, Anand BS and Singal AK: Management of hepatocellular carcinoma. J Cancer Res Clin Oncol. 141:861–876. 2015. View Article : Google Scholar : PubMed/NCBI
2	El-Serag HB: Hepatocellular carcinoma. N Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
3	Takayama T: Surgical treatment for hepatocellular carcinoma. Jpn J Clin Oncol. 41:447–454. 2011. View Article : Google Scholar : PubMed/NCBI
4	Sengupta B and Siddiqi SA: Hepatocellular carcinoma: Important biomarkers and their significance in molecular diagnostics and therapy. Curr Med Chem. 19:3722–3729. 2012. View Article : Google Scholar : PubMed/NCBI
5	Schütte K, Schulz C, Link A and Malfertheiner P: Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis. World J Hepatol. 7:139–149. 2015. View Article : Google Scholar : PubMed/NCBI
6	Saito Y, Shimada M, Utsunomiya T, Morine Y, Imura S, Ikemoto T, Mori H, Hanaoka J, Yamada S and Asanoma M: Prediction of recurrence of hepatocellular carcinoma after curative hepatectomy using preoperative Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein. Hepatol Res. 42:887–894. 2012. View Article : Google Scholar : PubMed/NCBI
7	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
8	Wallace DC: Mitochondria and cancer. Nat Rev Cancer. 12:685–698. 2012. View Article : Google Scholar : PubMed/NCBI
9	Eboli ML, Paradies G, Galeotti T and Papa S: Pyruvate transport in tumour-cell mitochondria. Biochim Biophys Acta. 460:183–187. 1977. View Article : Google Scholar : PubMed/NCBI
10	Paradies G, Capuano F, Palombini G, Galeotti T and Papa S: Transport of pyruvate in mitochondria from different tumor cells. Cancer Res. 43:5068–5071. 1983.PubMed/NCBI
11	Yang C, Ko B, Hensley CT, Jiang L, Wasti AT, Kim J, Sudderth J, Calvaruso MA, Lumata L, Mitsche M, et al: Glutamine oxidation maintains the TCA cycle and cell survival during impaired mitochondrial pyruvate transport. Mol Cell. 56:414–424. 2014. View Article : Google Scholar : PubMed/NCBI
12	Herzig S, Raemy E, Montessuit S, Veuthey JL, Zamboni N, Westermann B, Kunji ER and Martinou JC: Identification and functional expression of the mitochondrial pyruvate carrier. Science. 337:93–96. 2012. View Article : Google Scholar : PubMed/NCBI
13	Bricker DK, Taylor EB, Schell JC, Orsak T, Boutron A, Chen YC, Cox JE, Cardon CM, Van Vranken JG, Dephoure N, et al: A mitochondrial pyruvate carrier required for pyruvate uptake in yeast, Drosophila, and humans. Science. 337:96–100. 2012. View Article : Google Scholar : PubMed/NCBI
14	Schell JC, Olson KA, Jiang L, Hawkins AJ, Van Vranken JG, Xie J, Egnatchik RA, Earl EG, DeBerardinis RJ and Rutter J: A role for the mitochondrial pyruvate carrier as a repressor of the Warburg effect and colon cancer cell growth. Mol Cell. 56:400–413. 2014. View Article : Google Scholar : PubMed/NCBI
15	Wang CJ, Zhou ZG, Holmqvist A, Zhang H, Li Y, Adell G and Sun XF: Survivin expression quantified by image pro-plus compared with visual assessment. Appl Immunohistochem Mol Morphol. 17:530–535. 2009. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Llovet JM, Brú C and Bruix J: Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis. 19:329–338. 1999. View Article : Google Scholar : PubMed/NCBI
18	de Sousa Abreu R, Penalva LO, Marcotte EM and Vogel C: Global signatures of protein and mRNA expression levels. Mol Biosyst. 5:1512–1526. 2009.PubMed/NCBI
19	Vigueira PA, McCommis KS, Schweitzer GG, Remedi MS, Chambers KT, Fu X, McDonald WG, Cole SL, Colca JR, Kletzien RF, et al: Mitochondrial pyruvate carrier 2 hypomorphism in mice leads to defects in glucose-stimulated insulin secretion. Cell Rep. 7:2042–2053. 2014. View Article : Google Scholar : PubMed/NCBI
20	Maluccio M and Covey A: Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin. 62:394–399. 2012. View Article : Google Scholar : PubMed/NCBI
21	Gluer AM, Cocco N, Laurence JM, Johnston ES, Hollands MJ, Pleass HC, Richardson AJ and Lam VW: Systematic review of actual 10-year survival following resection for hepatocellular carcinoma. HPB (Oxford). 14:285–290. 2012. View Article : Google Scholar : PubMed/NCBI
22	Morise Z, Kawabe N, Tomishige H, Nagata H, Kawase J, Arakawa S, Yoshida R and Isetani M: Recent advances in the surgical treatment of hepatocellular carcinoma. World J Gastroenterol. 20:14381–14392. 2014. View Article : Google Scholar : PubMed/NCBI
23	Vacanti NM, Divakaruni AS, Green CR, Parker SJ, Henry RR, Ciaraldi TP, Murphy AN and Metallo CM: Regulation of substrate utilization by the mitochondrial pyruvate carrier. Mol Cell. 56:425–435. 2014. View Article : Google Scholar : PubMed/NCBI
24	Gray LR, Sultana MR, Rauckhorst AJ, Oonthonpan L, Tompkins SC, Sharma A, Fu X, Miao R, Pewa AD, Brown KS, et al: Hepatic mitochondrial pyruvate carrier 1 is required for efficient regulation of gluconeogenesis and whole-body glucose homeostasis. Cell Metab. 22:669–681. 2015. View Article : Google Scholar : PubMed/NCBI
25	Ma R, Zhang W, Tang K, Zhang H, Zhang Y, Li D, Li Y, Xu P, Luo S, Cai W, et al: Switch of glycolysis to gluconeogenesis by dexamethasone for treatment of hepatocarcinoma. Nat Commun. 4:25082013. View Article : Google Scholar : PubMed/NCBI
26	Divakaruni AS, Wiley SE, Rogers GW, Andreyev AY, Petrosyan S, Loviscach M, Wall EA, Yadava N, Heuck AP, Ferrick DA, et al: Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc Natl Acad Sci USA. 110:5422–5427. 2013. View Article : Google Scholar : PubMed/NCBI
27	Du J, Cleghorn WM, Contreras L, Lindsay K, Rountree AM, Chertov AO, Turner SJ, Sahaboglu A, Linton J, Sadilek M, et al: Inhibition of mitochondrial pyruvate transport by zaprinast causes massive accumulation of aspartate at the expense of glutamate in the retina. J Biol Chem. 288:36129–36140. 2013. View Article : Google Scholar : PubMed/NCBI
28	Compan V, Pierredon S, Vanderperre B, Krznar P, Marchiq I, Zamboni N, Pouyssegur J and Martinou JC: Monitoring mitochondrial pyruvate carrier activity in real time using a BRET-based biosensor: Investigation of the warburg effect. Mol Cell. 59:491–501. 2015. View Article : Google Scholar : PubMed/NCBI